Evolva Holding SA (EVE.SW)

CHF 0.84

(-6.44%)

Operating Expenses Summary of Evolva Holding SA

  • Evolva Holding SA's latest annual operating expenses in 2023 was 89.66 Million CHF , down -74.77% from previous year.
  • Evolva Holding SA's latest quarterly operating expenses in 2024 Q2 was -1.31 Million CHF , down 0.0% from previous quarter.
  • Evolva Holding SA reported a annual operating expenses of 14.46 Million CHF in annual operating expenses 2022, down -11.4% from previous year.
  • Evolva Holding SA reported a annual operating expenses of 16.32 Million CHF in annual operating expenses 2021, up 43.34% from previous year.
  • Evolva Holding SA reported a quarterly operating expenses of 6.56 Million CHF for 2023 Q2, down 0.0% from previous quarter.
  • Evolva Holding SA reported a quarterly operating expenses of -83.84 Million CHF for 2023 Q4, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Evolva Holding SA (2023 - 2005)

Historical Annual Operating Expenses of Evolva Holding SA (2023 - 2005)

Year Operating Expenses Operating Expenses Growth
2023 89.66 Million CHF -74.77%
2022 14.46 Million CHF -11.4%
2021 16.32 Million CHF 43.34%
2020 11.39 Million CHF -35.53%
2019 17.66 Million CHF -46.58%
2018 33.07 Million CHF -30.73%
2017 47.74 Million CHF 233.82%
2016 14.3 Million CHF 17.13%
2015 12.21 Million CHF 25.97%
2014 9.69 Million CHF 31.85%
2013 7.35 Million CHF -72.84%
2012 27.06 Million CHF 184.28%
2011 9.52 Million CHF -77.19%
2010 41.74 Million CHF 51.09%
2009 27.62 Million CHF -51.75%
2008 57.26 Million CHF -5.25%
2007 60.43 Million CHF -18.21%
2006 73.88 Million CHF 102.6%
2005 36.47 Million CHF 0.0%

Peer Operating Expenses Comparison of Evolva Holding SA

Name Operating Expenses Operating Expenses Difference
Addex Therapeutics Ltd 11.89 Million CHF -653.832%
BB Biotech AG -199.56 Million CHF 144.929%
Basilea Pharmaceutica AG 111.63 Million CHF 19.682%
Idorsia Ltd 400.38 Million CHF 77.606%
Kuros Biosciences AG 36.21 Million CHF -147.557%
Molecular Partners AG 20.3 Million CHF -341.645%
Relief Therapeutics Holding AG 114.94 Million CHF 21.992%
Santhera Pharmaceuticals Holding AG 31.33 Million CHF -186.142%